REGRANEX Gel actively stimulates angiogenesis and granulation tissue formation.

Demonstrates biological activity similar to that of endogenous PDGF Promotes recruitment and proliferation of chemotactic cells, including monocytes and fibroblasts, necessary for stimulation of a variety of wound healing processes and aiding in the creation of granulation tissue The first and only prescription growth factor clinically proven to actively stimulate granulation tissue formation and enhance natural wound healing

Indication

REGRANEX Gel is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. When used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control, REGRANEX Gel increases the incidence of complete healing of diabetic ulcers.

The efficacy of REGRANEX Gel has not been established for the treatment of pressure ulcers and venous stasis ulcers (see Clinical Studies in Full Prescribing Information), and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue (Stage I or II, IAET staging classification) or ischemic diabetic ulcers.

Click here for PATHways to Healing: A treatment approach to wound healing with technology-based solutions